0001209191-20-054610.txt : 20201013 0001209191-20-054610.hdr.sgml : 20201013 20201013154256 ACCESSION NUMBER: 0001209191-20-054610 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201012 FILED AS OF DATE: 20201013 DATE AS OF CHANGE: 20201013 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH SANDFORD D CENTRAL INDEX KEY: 0001243004 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38137 FILM NUMBER: 201236178 MAIL ADDRESS: STREET 1: C/O ARIAD PHARMACEUTICALS INC STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AKCEA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001662524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472608175 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 22 BOSTON WHARF RD STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-207-0202 MAIL ADDRESS: STREET 1: 22 BOSTON WHARF RD STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-12 1 0001662524 AKCEA THERAPEUTICS, INC. AKCA 0001243004 SMITH SANDFORD D C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210 1 0 0 0 Stock Option (right to buy) 12.21 2020-10-12 4 D 0 52837 5.94 D 2027-06-04 Common Stock 52837 0 D Stock Option (right to buy) 16.14 2020-10-12 4 D 0 26400 2.01 D 2030-04-12 Common Stock 26400 0 D This option, which provided that 25% of the shares would vest in equal yearly installments over four years on the anniversary of March 13, 2017, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $313,851.78, representing the difference between the exercise price of the option and the acquisition price of $18.15. This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. /s/ Joshua F. Patterson, Attorney-in-Fact 2020-10-12